Editas Medicine (EDIT) Stock Price, News & Analysis

Company Overview

Editas Medicine is a biotechnology company focused on the development of genome editing therapies to treat a range of serious diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company harnesses CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) gene-editing platforms to design precision medicines that directly target the underlying genetic causes of disease. Editas Medicine’s vision centers on advancing in vivo and ex vivo gene editing solutions for patients with inherited retinal disorders, hematologic conditions, and other rare diseases with high unmet medical need.

The company’s pipeline includes multiple product candidates in various stages of clinical and preclinical development. The most advanced program, EDIT-101, is designed to treat Leber congenital amaurosis type 10 (LCA10), a hereditary retinal disorder that causes early-onset vision loss. In addition, Editas is advancing ex vivo cell therapies such as EDIT-301 for sickle cell disease and beta-thalassemia, utilizing engineered hematopoietic stem cells to correct pathogenic mutations. Earlier-stage research leverages proprietary delivery technologies and novel editor variants to expand the reach of gene editing beyond the eye and blood, positioning the company to address additional genetic and ocular diseases.

Since its inception, Editas Medicine has built partnerships with leading pharmaceutical and academic institutions across North America, Europe and Asia to accelerate research and development. The company maintains research collaborations with global organizations to refine delivery vectors, optimize editing efficiency, and ensure the safety of its therapeutic candidates. These alliances amplify Editas Medicine’s capabilities in translational science while facilitating ultimate patient access through potential co-development and commercialization pathways.

Leadership at Editas Medicine combines scientific expertise with biopharmaceutical experience. The executive team, led by President and Chief Executive Officer Gilmore O’Neill, includes seasoned professionals in gene editing, clinical development and regulatory affairs. The company’s board and scientific advisory committees feature pioneers in molecular biology and genetics, guiding strategic decisions as Editas Medicine works toward its goal of bringing transformative, precisely targeted treatments to patients worldwide.

Key Stats

• Today's Range: $2.99 to $3.18
• 50-Day Range: $1.33 to $3.08
• 52-Week Range: $0.91 to $6.05
• Volume: 2.56 million shs
• Average Volume: 2.65 million shs
• Market Capitalization: $256.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.70
• Consensus Rating: Hold

Editas Medicine Stock Analysis - MarketRank™

Editas Medicine scored higher than 81% of companies evaluated by MarketBeat, and ranked 192nd out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Editas Medicine has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 2 buy ratings, 7 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Editas Medicine has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Editas Medicine are expected to grow in the coming year, from ($2.71) to ($1.66) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Editas Medicine is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Editas Medicine is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Editas Medicine has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.29% of the float of Editas Medicine has been sold short.

Short Interest Ratio / Days to Cover

Editas Medicine has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Editas Medicine has recently decreased by 6.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Editas Medicine does not currently pay a dividend.

Dividend Growth

Editas Medicine does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.15

Percentage of Shares Shorted

10.29% of the float of Editas Medicine has been sold short.

Short Interest Ratio / Days to Cover

Editas Medicine has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Editas Medicine has recently decreased by 6.33%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Editas Medicine this week, compared to 5 articles on an average week.

Search Interest

13 people have searched for EDIT on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.

MarketBeat Follows

7 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,146.00 in company stock.

Percentage Held by Insiders

Only 2.10% of the stock of Editas Medicine is held by insiders.

Percentage Held by Institutions

71.90% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EDIT Stock Analysis - Frequently Asked Questions

How have EDIT shares performed this year?

Editas Medicine's stock was trading at $1.27 at the beginning of the year. Since then, EDIT shares have increased by 140.9% and is now trading at $3.06.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) announced its quarterly earnings data on Monday, May, 12th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.08. The company had revenue of $4.66 million for the quarter, compared to the consensus estimate of $0.79 million. Editas Medicine had a negative trailing twelve-month return on equity of 139.24% and a negative net margin of 701.06%.

When did Editas Medicine IPO?

Editas Medicine (EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Who are Editas Medicine's major shareholders?

Editas Medicine's top institutional shareholders include Wealth Enhancement Advisory Services LLC (0.06%). Insiders that own company stock include Gilmore Neil O'neill, Baisong Mei, Michelle Robertson, Bruce Eaton, Linda Burkly, Jessica Hopfield, Mark S Shearman and Amy Parison.
View institutional ownership trends.

How do I buy shares of Editas Medicine?

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Editas Medicine investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Tesla (TSLA), Enovix (ENVX) and Luminar Technologies (LAZR).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EDIT
• CIK: 1650664
• Web: www.editasmedicine.com
• Phone: (617) 401-9000
• Fax: N/A
• Employees: 230
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Editas Medicine: $4.70
• High Price Target: $12.00
• Low Price Target: $1.00
• Potential Upside/Downside: +53.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.31
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$237.09 million
• Net Margins: -701.06%
• Pretax Margin: -701.06%
• Return on Equity: -139.24%
• Return on Assets: -63.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.08
• Quick Ratio: 3.08

Sales & Book Value

• Annual Sales: $32.31 million
• Price / Sales: 7.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.63 per share
• Price / Book: 1.88

Miscellaneous

• Outstanding Shares: 83,710,000
• Free Float: 81,955,000
• Market Cap: $256.15 million
• Optionable: Optionable
• Beta: 2.15